A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 STUDY OF RUCAPARIB AS SWITCH MAINTENANCE FOLLOWING PLATINUM-BASED CHEMOTHERAPY IN PATIENTS WITH PLATINUM-SENSITIVE, HIGH-GRADE SEROUS OR ENDOMETRIOID EPITHELIAL OVARIAN, PRIMARY PERITONEAL OR FALLOPIAN TUBE CANCER

Registry ID

CO-338-014

Source registry

HEALTH_CANADA

Status

Closed

Phase

PHASE3

Study type

INTERVENTIONAL

Sponsor

CLOVIS ONCOLOGY INC

Start date

2016-10-26

Completion date

2022-04-18

Last update

2013-11-08

Conditions

• OVARIAN CANCER PRIMARY PERITONEAL
• OVARIAN CANCER

Related clinical trials

• A PHASE 3, RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY OF SACITUZUMAB TIRUMOTECAN (SAC-TMT, MK-2870) MAINTENANCE TREATMENT WITH OR WITHOUT BEVACIZUMAB VERSUS STANDARD OF CARE IN PARTICIPANTS WITH NEWLY DIAGNOSE ADVANCED HRD-NEGATIVE OVARIAN CANCER FOLLOWING FIRST-LINE PLATINUMBASED CHEMOTHERAPY (TROFUSE-021/ENGOTOV85/GOG-3102)
• A RANDOMIZED, OPEN-LABEL, MULTICENTER, PHASE 3 STUDY TO INVESTIGATE GSK5733584 COMPARED WITH CHEMOTHERAPY IN PARTICIPANTS WITH PLATINUM-RESISTANT OVARIAN CANCER
• A PHASE 3, RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF SACITUZUMAB TIRUMOTECAN (MK-2870) MAINTENANCE TREATMENT WITH OR WITHOUT BEVACIZUMAB VERSUS STANDARD OF CARE AFTER SECOND-LINE PLATINUM-BASED DOUBLET CHEMOTHERAPY IN PARTICIPANTS WITH PLATINUM-SENSITIVE RECURRENT OVARIAN CANCER (TROFUSE-022/ENGOT-OV84/GOG-3103)
• CATALINA-2: A PHASE 2 STUDY EVALUATING THE EFFICACY AND SAFETY OF TORL-1-23 IN WOMEN WITH ADVANCED PLATINUM-RESISTANT EPITHELIAL OVARIAN CANCER (INCLUDING PRIMARY PERITONEAL AND FALLOPIAN TUBE CANCERS) EXPRESSING CLAUDIN 6 (CLDN6)
• A RANDOMIZED PHASE 2 STUDY OF OCULAR TOXICITY EVALUATION AND MITIGATION DURING TREATMENT WITH MIRVETUXIMAB SORAVTANSINE IN PATIENTS WITH RECURRENT OVARIAN CANCER WITH HIGH FOLATE RECEPTOR-ALPHA EXPRESSION
• A PHASE 1, FIRST-IN-HUMAN, OPEN-LABEL, DOSE-ESCALATION AND EXPANSION STUDY OF IMGN151 (ANTI-FR¿ ANTIBODY-DRUG CONJUGATE) IN ADULT PATIENTS WITH RECURRENT ENDOMETRIAL CANCER AND RECURRENT, HIGH-GRADE SEROUS EPITHELIAL OVARIAN, PRIMARY PERITONEAL, OR FALLOPIAN TUBE CANCERS

View on source registry